FDA Clears Denali Drug for Hunter Syndrome Amid Tightened Rare-Disease Scrutiny
TL;DR Summary
The FDA approved Denali Therapeutics' Avlayah for Hunter syndrome, marking a rare-disease drug approval at a time regulators are signaling tougher evidentiary standards after recent rejections like Regenxbio's Hunter syndrome gene therapy.
- FDA approves Denali Therapeutics drug for Hunter syndrome | STAT statnews.com
- Denali Therapeutics, Corcept Therapeutics win FDA approvals statnews.com
- FDA approves Denali's Hunter syndrome drug, handing rare disease community a win Fierce Pharma
- US FDA approves Denali's genetic disorder therapy for children Reuters
- Denali stock gains on FDA nod for lead asset (DNLI:NASDAQ) Seeking Alpha
Reading Insights
Total Reads
0
Unique Readers
6
Time Saved
2 min
vs 2 min read
Condensed
92%
380 → 32 words
Want the full story? Read the original article
Read on statnews.com